
pmid: 24366229
handle: 20.500.11768/119506
In 2013, several new IBD drugs, including golimumab and vedolizumab, have been approved or completed successful programmes, showing efficacy in both Crohn’s disease and ulcerative colitis. In addition, classic IBD drugs have been formulated for colonic delivery, such as budesonide MMX®, which was recently approved for mild-to-moderate ulcerative colitis.
Biological Factors, Treatment Outcome, Anti-Inflammatory Agents, Antibodies, Monoclonal, Humans, Antibodies, Monoclonal, Humanized, Budesonide, Inflammatory Bowel Diseases
Biological Factors, Treatment Outcome, Anti-Inflammatory Agents, Antibodies, Monoclonal, Humans, Antibodies, Monoclonal, Humanized, Budesonide, Inflammatory Bowel Diseases
| citations The total number of citations received by all articles of the researcher of interest. | 10 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
